Centessa Pharmaceuticals【0ACX】銘柄情報

Rendering Error

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.00

始値

時刻

15.6543

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

発行済株式数

0.00

配当利回り

PER

0.00

1 株当たり利益 (EPS)

歳入

6.85M

純利益

-151.09M

セクター

Coml Physical, Biologcl Resh

業界

Coml Physical, Biologcl Resh

ウェブサイト

www.centessa.com

本社

Cheshire, Gbr

設立

Centessa Pharmaceuticals Plc is listed in the Coml Physical, Biologcl Resh sector of the ロンドン証券取引所 with ticker 0ACX. The last closing price for Centessa Pharmaceuticals was US$0. Over the last year, Centessa Pharmaceuticals shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Centessa Pharmaceuticals currently has 0 shares in issue.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACX - Frequently Asked Questions (FAQ)

What is the current Centessa Pharmaceuticals share price?

The current share price of Centessa Pharmaceuticals is US$ 0.00

What is the 1 year trading range for Centessa Pharmaceuticals share price?

Centessa Pharmaceuticals has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the reporting currency for Centessa Pharmaceuticals?

Centessa Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Centessa Pharmaceuticals?

The latest annual turnover of Centessa Pharmaceuticals is USD 6.85M

What is the latest annual profit for Centessa Pharmaceuticals?

The latest annual profit of Centessa Pharmaceuticals is USD -151.09M

What is the registered address of Centessa Pharmaceuticals?

The registered address for Centessa Pharmaceuticals is 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE, WA14 2DT

What is the Centessa Pharmaceuticals website address?

The website address for Centessa Pharmaceuticals is www.centessa.com

Which industry sector does Centessa Pharmaceuticals operate in?

Centessa Pharmaceuticals operates in the COML PHYSICAL, BIOLOGCL RESH sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
AMGOAmigo Holdings Plc	0.475p (72.73%)	11.81M
BEMBeowulf Mining Plc	22.00p (25.71%)	104.2k
WSGWestminster Group Plc	1.30p (23.81%)	1.4M
BLOEBlock Energy Plc	1.00p (21.21%)	11.06M
SMLStrategic Minerals Plc	0.30p (20.00%)	11.23M
SSTScottish Oriental Smaller Companies Trust Plc	290.00p (-95.96%)	76.08k
ONCOncimmune Holdings Plc	1.40p (-43.78%)	1.57M
BMTOBraime Group Plc	1,350.00p (-20.59%)	547
PYXPyx Resources Limited	1.97p (-19.76%)	398.74k
MGAMMorgan Advanced Materials Plc	214.50p (-16.21%)	8.59M
TRPTower Resources Plc	0.0245p (6.52%)	775.51M
UKOGUk Oil & Gas Plc	0.01125p (-4.26%)	434.61M
TW.Taylor Wimpey Plc	114.25p (2.05%)	345.64M
LLOYLloyds Banking Group Plc	72.32p (0.84%)	344.78M
PREMPremier African Minerals Limited	0.0205p (-11.26%)	300.49M

Rendering Error

phrocks 7分前

That's old news

HMBL

Peter J 9分前

Obessed with ERHC, desperately trying to get some substantial amounts of shares...
"There was a reason why I only threw $12 in the pot here."
That equates to 282 ERHC posts per invested dollar... 😂😂😂

And on top of that he owns Birkshire Hathaway

ERHE

carvajal 13分前

Exciting times ! https://www.semiconductor-today.com/news_items/2024/may/nuburu-070524.shtml

HMBL

WooptdooU 19分前

lwlg appears to have damaged many more lives, just for their CASH TAKE and INSIDER SELLS from. Nasdq uplisting...pity, really

LWLG

edbi46 19分前

On REDDIT 3 months ago:
RecoveryRx now available through prosthetics for pain management, ortho, PT
Veterans Health Administration
VA providers now have access to recently FDA-approved non-opioid, non-invasive pain management device through RecoveryRx. RecoveryRx produces an el

BMI LMT QUBT

carvajal 21分前

Former Foxconn CTO and CIO currently works at $BURU , Thiago ain't playing around.

BURU

WooptdooU 22分前

The remaining CASH is their target...for themselves...eom

LWLG

nowwhat2 22分前

Well that was pretty nasty......My goodness.
Sheesh

WooptdooU 23分前

More details of the Csah Take by the bod NEEDS to be litigated.
marcinobodi TOOK, return to the scheme scene UNadmiral perpetrated, bocci benefitted too.

LWLG

Nebuchadnezzar 27分前

yes, i understand that, but i was referring to an SEC FORM 4

Form 4 is a two-page document that must be filed with the SEC within two days of the transaction. It is used to inform the public that an insider transaction has taken place, as well as to provide details about the timing, t

RITE

236T568 41分前

He was in the room sitting in the first row of the crowd behind the Ukrainian's that were sitting on the couch

Something that seems strange to me: Where was the odious Pete Hegseth? He is, after all, Secretary of Defense. Did Trump--or perhaps Rubio, with Trump's consent--fear he'd sa

236T568 43分前

Dozens of dead birds found on Long Island beach believed to have died from avian flu

Residents of Patchogue Shores are staying away from the beach for now, hoping the issue will be resolved as the weather gets warmer.

https://www.nbcnews.com/news/rcna194174

SkeBallLarry 44分前

Rada deputy called for Zelensky's impeachment after his >

failure in the United States >
https://news-pravda.com/world/2025/02/28/1099576.html

SkeBallLarry 44分前

Rada deputy called for Zelensky's impeachment after his >

failure in the United States >
https://news-pravda.com/world/2025/02/28/1099576.html

SkeBallLarry 44分前

Rada deputy called for Zelensky's impeachment after his >

failure in the United States >
https://news-pravda.com/world/2025/02/28/1099576.html

SkeBallLarry 45分前

Rada deputy called for Zelensky's impeachment after his >

failure in the United States >
https://news-pravda.com/world/2025/02/28/1099576.html

Bull_Dolphin 46分前

Ka$h says no honey in honeypot:

FBI’s Patel says Trump 'honeypot' story not true, defends female agent
Conservative media reported a whistleblower provided evidence the FBI under former Director James Comey ran a “honeypot” operation against Trump to try to entrap him as far ba

RealDutch 46分前

I just don't see the issue.

A) The stablecoins will trade publicly. They will even act as a new currency as this is what the banks want.

B) as for our equity tokens,

1) it would be stupid to sell now if the value could easily be 10x higher in a years time

ITUP

P-Rawl 46分前

I posted this about Vito and James almost a year ago :
https://investorshub.advfn.com/boards/replies.aspx?msg=174053177 https://investorshub.advfn.com/boards/replies.aspx?msg=174053177

SONG

eagle8 51分前

https://x.com/AllenTurner206/status/1895536152679235975

NWBO

MoneyMaker111 54分前

AMC: nothing wrong with these awesome prices

AMC

SkeBallLarry 55分前

UpDate from DOGE >

Latest work
Follow on
DOGE
Department of Government Efficiency
@DOGE
Today NIH canceled grants for ~$10.9 million including:
-$1.7M for the “China Health and Retirement Longitudinal study” at Peking University in Beijing, Ch

SkeBallLarry 55分前

SkeBallLarry 56分前

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Centessa Pharmaceuticals Plc (0ACX)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Centessa Pharmaceuticals Plc について

0ACX 最新ニュース

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

ムーバー

0ACX 財務

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Centessa Pharmaceuticals Plc (0ACX) 銘柄情報

Centessa Pharmaceuticals Plc (0ACX)

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Centessa Pharmaceuticals Plc について

0ACX 最新ニュース

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

ムーバー

0ACX 財務

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE